Sterling Capital Management’s Protalix BioTherapeutics PLX Stock Holding History

Sterling Capital Management’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$6.7K	Buy	2,429 +2,169	+834%	+$5.4K	﹤0.01%	2726
2026 Q2	$606	Sell	260 -193	-43%	-$409	﹤0.01%	3206
2026 Q1	$983	Hold	453	–	–	﹤0.01%	3100
2025 Q4	$815	Buy	453 +284	+168%	+$581	﹤0.01%	3153
2025 Q3	$375	Buy	169 +1	+0.6%	+$2	﹤0.01%	3181
2025 Q2	$249	Buy	+168	New	+$344	﹤0.01%	3222

Other funds holding PLX

Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return

Bailard Foster City, California $4.94B AUM 25.15% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

OGF

Orin Green Financial San Diego, California $267M AUM 12.91% 1-Year Est. Return

TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return

Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

Investment Research & Advisory Group Atlanta, Georgia $337M AUM 19.8% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Activest Wealth Management Aventure, Florida $540M AUM 34.92% 1-Year Est. Return

Sterling Capital Management's PLX Position: Q3 2026 in Review

Sterling Capital Management increased its Protalix BioTherapeutics (PLX) stake by 834% in Q3 2026, buying an estimated $5.4K and bringing the position to 2,429 shares worth $6.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2726.

Sterling Capital Management first reported a position in PLX in Q2 2025 and has held it in 6 quarters since. 13 funds tracked by Wall St. Rank hold PLX as of Q3 2026.

Sterling Capital Management held 2,429 shares of Protalix BioTherapeutics worth $6.7K as of Q3 2026.
Sterling Capital Management bought 2,169 Protalix BioTherapeutics shares in Q3 2026, an estimated $5.4K.
Protalix BioTherapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #2726 holding.
Sterling Capital Management first reported a position in Protalix BioTherapeutics in Q2 2025 and has held it in 6 quarters since.
13 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2026.

Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.